FDA issues EUA for new COVID-19 treatment

Casirivimab and imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells. A clinical trial of patients with COVID-19 found that administering casirivimab and imdevimab together reduced COVID-19-related hospitalizations or emergency department visits in patients at high risk for disease progression within 28 days after treatment when compared with placebo.